MA34768B1 - Comprimé orodispersible - Google Patents
Comprimé orodispersibleInfo
- Publication number
- MA34768B1 MA34768B1 MA36063A MA36063A MA34768B1 MA 34768 B1 MA34768 B1 MA 34768B1 MA 36063 A MA36063 A MA 36063A MA 36063 A MA36063 A MA 36063A MA 34768 B1 MA34768 B1 MA 34768B1
- Authority
- MA
- Morocco
- Prior art keywords
- active ingredient
- pharmaceutically active
- lansoprazole
- pellets
- copolymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Abstract
L'INVENTION CONCERNE UN COMPRIMÉ ORODISPERSIBLE OBTENU PAR COMPRESSION DE GRANULÉS FINS PRÉSENTANT UNE LIBÉRATION CONTRÔLÉE DE LANSOPRAZOLE ET D'UN ADDITIF, PERMETTANT DE SUPPRIMER LA RUPTURE DES GRANULÉS FINS PENDANT LA FORMATION DE COMPRIMÉS ET DE CONTRÔLER LA LIBÉRATION DE LANSOPRAZOLE SUR UNE LONGUE DURÉE, ET POUVANT MAINTENIR UNE CONCENTRATION THÉRAPEUTIQUEMENT EFFICACE PENDANT UNE DURÉE PROLONGÉE, ET PRÉSENTANT UNE MEILLEURE PROPRIÉTÉ DE DISPERSION DANS LA CAVITÉ BUCCALE. LE COMPRIMÉ ORODISPERSIBLE SELON L'INVENTION COMPREND : (I) DES GRANULÉS FINS PRÉSENTANT UNE LIBÉRATION CONTRÔLÉE D'UN INGRÉDIENT PHARMACEUTIQUEMENT ACTIF CONTENANT DES GRANULÉS FINS RENFERMANT UN INGRÉDIENT PHARMACEUTIQUEMENT ACTIF ET UNE COUCHE D'ENROBAGE CONTENANT UN COPOLYMÈRE ACIDE MÉTHACRYLIQUE/ACRYLATE DE MÉTHYLE/¨MÉTHACRYLATE DE MÉTHYLE, LES GRANULÉS FINS QUI RENFERMENT UN INGRÉDIENT PHARMACEUTIQUEMENT ACTIF ÉTANT ENROBÉS D'UNE QUANTITÉ SUPÉRIEURE À 80 % EN POIDS ET NE DÉPASSANT PAS 300 % EN POIDS DUDIT COPOLYMÈRE, ET (II) DES GRANULÉS FINS PRÉSENTANT UNE LIBÉRATION CONTRÔLÉE D'UN INGRÉDIENT PHARMACEUTIQUEMENT ACTIF QUI COMPORTE L'INGRÉDIENT PHARMACEUTIQUEMENT ACTIF ET UNE COUCHE D'ENROBAGE COMPRENANT (A) UN COPOLYMÈRE ACRYLATE D'ÉTHYLE/MÉTHACRYLATE DE MÉTHYLE ET (B) UN OU PLUSIEURS TYPES DE POLYMÈRES SÉLECTIONNÉS DANS LE GROUPE COMPRENANT LES ÉLÉMENTS : COPOLYMÈRE ACIDE MÉTHACRYLIQUE/ACRYLATE D'ÉTHYLE, PHTALATE HYPROMELLOSE, CARBOXYMÉTHYLÉTHYLCELLULOSE, PHTALATE ACÉTATE POLYVINYLIQUE, SUCCINATE ACÉTATE MÉTHYLCELLULOSE D'HYDROXYPROPYLE ET PHTALATE ACÉTATE DE CELLULOSE. LES GRANULÉS FINS (I) ET LES GRANULÉS FINS (II) PRÉSENTENT UNE GRANULOMÉTRIE MOYENNE NE DÉPASSANT PAS 500 MICROMÈTRES, ET L'INGRÉDIENT PHARMACEUTIQUEMENT ACTIF EST DU LANSOPRAZOLE OU UNE FORME OPTIQUEMENT ACTIVE DU LANSOPRAZOLE OU ENCORE UN SEL DU LANSOPRAZOLE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061427384P | 2010-12-27 | 2010-12-27 | |
PCT/JP2011/080568 WO2012091153A2 (fr) | 2010-12-27 | 2011-12-26 | Comprimé orodispersible |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34768B1 true MA34768B1 (fr) | 2013-12-03 |
Family
ID=45509604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36063A MA34768B1 (fr) | 2010-12-27 | 2013-06-28 | Comprimé orodispersible |
Country Status (23)
Country | Link |
---|---|
US (1) | US20130273157A1 (fr) |
EP (1) | EP2658530A2 (fr) |
JP (1) | JP2014501224A (fr) |
KR (1) | KR20140007364A (fr) |
CN (1) | CN103402500A (fr) |
AR (1) | AR084610A1 (fr) |
AU (1) | AU2011350396A1 (fr) |
BR (1) | BR112013014875A2 (fr) |
CA (1) | CA2823166C (fr) |
CL (1) | CL2013001793A1 (fr) |
CO (1) | CO6731132A2 (fr) |
CR (1) | CR20130327A (fr) |
EA (1) | EA028217B1 (fr) |
EC (1) | ECSP13012718A (fr) |
MA (1) | MA34768B1 (fr) |
MX (1) | MX2013007588A (fr) |
PE (1) | PE20141115A1 (fr) |
SG (2) | SG10201602311XA (fr) |
TN (1) | TN2013000220A1 (fr) |
TW (1) | TW201304823A (fr) |
UY (1) | UY33841A (fr) |
WO (1) | WO2012091153A2 (fr) |
ZA (1) | ZA201304617B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009113703A2 (fr) | 2008-03-11 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Préparation solide orodispersible |
PT2797416T (pt) | 2011-12-28 | 2017-10-23 | Global Blood Therapeutics Inc | Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
GB201303781D0 (en) | 2013-03-04 | 2013-04-17 | Gauthier Pierre Pascal | Oral timer device and method of using same |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
MY180206A (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
DK3102208T3 (da) | 2014-02-07 | 2021-03-08 | Global Blood Therapeutics Inc | Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd |
CA2966631A1 (fr) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | Procedes et intermediaires destines a la preparation d'ethers de dialcane a terminaison acide alpha, omega-acide dicarboxylique |
EP3288556A4 (fr) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Compositions à désintégration par voie orale |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
TWI778983B (zh) * | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
US20190008779A1 (en) * | 2017-05-11 | 2019-01-10 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
WO2019013310A1 (fr) * | 2017-07-10 | 2019-01-17 | Takeda Pharmaceutical Company Limited | Préparation comprenant du vonoprazan |
CN108576205B (zh) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种草莓联合干燥的处理方法 |
WO2020072377A1 (fr) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulateurs de l'hémoglobine pour le traitement de la drépanocytose |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
JP3069458B2 (ja) | 1992-01-29 | 2000-07-24 | 武田薬品工業株式会社 | 口腔内崩壊型錠剤およびその製造法 |
JP2919771B2 (ja) | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤 |
JPH0948726A (ja) | 1995-08-07 | 1997-02-18 | Tanabe Seiyaku Co Ltd | 口腔内速崩壊性製剤およびその製法 |
TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | 2−(2−ピリジルメチルスルフィニル)ベンズイミダゾール系化合物の結晶およびその製造法 |
DK1736144T3 (en) | 1998-05-18 | 2015-12-07 | Takeda Pharmaceutical | Orally disintegrating tablets. |
ATE481090T1 (de) | 1998-07-28 | 2010-10-15 | Takeda Pharmaceutical | Leicht zerfallende feste zubereitung |
TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
DE60124692T2 (de) | 2000-04-28 | 2007-09-13 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten |
CA2762960C (fr) | 2000-05-15 | 2014-07-22 | Takeda Pharmaceutical Company Limited | Procedes de recristallisation pour obtenir du lansoprazole anhydre optiquement actif |
KR100887912B1 (ko) | 2000-12-01 | 2009-03-12 | 다케다 야쿠힌 고교 가부시키가이샤 | (r)- 또는 (s)-란소프라졸의 결정화 방법 |
JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
CA2558535A1 (fr) * | 2004-03-03 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | Composition pharmaceutique stable comprenant un medicament labile en milieu acide |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
WO2007078271A2 (fr) * | 2005-12-20 | 2007-07-12 | Teva Pharmaceutical Industries Ltd. | Comprimes a desintegration orale de lansoprazole |
EP1837016A3 (fr) * | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Composition pharmaceutique en multiple-unité |
WO2008081891A1 (fr) * | 2006-12-28 | 2008-07-10 | Takeda Pharmaceutical Company Limited | Préparation solide se désintégrant oralement |
WO2009113703A2 (fr) * | 2008-03-11 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Préparation solide orodispersible |
US20100015239A1 (en) * | 2008-07-17 | 2010-01-21 | Ahmed Salah U | Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same |
-
2011
- 2011-12-26 CN CN2011800685821A patent/CN103402500A/zh active Pending
- 2011-12-26 SG SG10201602311XA patent/SG10201602311XA/en unknown
- 2011-12-26 PE PE2013001471A patent/PE20141115A1/es not_active Application Discontinuation
- 2011-12-26 CA CA2823166A patent/CA2823166C/fr active Active
- 2011-12-26 BR BR112013014875A patent/BR112013014875A2/pt active Search and Examination
- 2011-12-26 EP EP11811174.9A patent/EP2658530A2/fr not_active Withdrawn
- 2011-12-26 US US13/997,862 patent/US20130273157A1/en not_active Abandoned
- 2011-12-26 MX MX2013007588A patent/MX2013007588A/es not_active Application Discontinuation
- 2011-12-26 TW TW100148775A patent/TW201304823A/zh unknown
- 2011-12-26 AU AU2011350396A patent/AU2011350396A1/en not_active Abandoned
- 2011-12-26 UY UY0001033841A patent/UY33841A/es not_active Application Discontinuation
- 2011-12-26 JP JP2013529237A patent/JP2014501224A/ja active Pending
- 2011-12-26 KR KR1020137019795A patent/KR20140007364A/ko not_active Application Discontinuation
- 2011-12-26 WO PCT/JP2011/080568 patent/WO2012091153A2/fr active Application Filing
- 2011-12-26 SG SG2013040944A patent/SG190905A1/en unknown
- 2011-12-26 EA EA201390981A patent/EA028217B1/ru not_active IP Right Cessation
- 2011-12-27 AR ARP110104955A patent/AR084610A1/es unknown
-
2013
- 2013-05-24 TN TNP2013000220A patent/TN2013000220A1/fr unknown
- 2013-06-19 CL CL2013001793A patent/CL2013001793A1/es unknown
- 2013-06-21 ZA ZA2013/04617A patent/ZA201304617B/en unknown
- 2013-06-25 EC ECSP13012718 patent/ECSP13012718A/es unknown
- 2013-06-27 CR CR20130327A patent/CR20130327A/es not_active Application Discontinuation
- 2013-06-28 MA MA36063A patent/MA34768B1/fr unknown
- 2013-07-25 CO CO13176405A patent/CO6731132A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201304617B (en) | 2014-08-27 |
WO2012091153A3 (fr) | 2012-09-07 |
SG190905A1 (en) | 2013-07-31 |
EA028217B1 (ru) | 2017-10-31 |
ECSP13012718A (es) | 2013-12-31 |
JP2014501224A (ja) | 2014-01-20 |
MX2013007588A (es) | 2013-08-09 |
EP2658530A2 (fr) | 2013-11-06 |
KR20140007364A (ko) | 2014-01-17 |
EA201390981A1 (ru) | 2014-07-30 |
TW201304823A (zh) | 2013-02-01 |
WO2012091153A2 (fr) | 2012-07-05 |
CA2823166A1 (fr) | 2012-07-05 |
PE20141115A1 (es) | 2014-09-12 |
CR20130327A (es) | 2013-08-22 |
UY33841A (es) | 2012-07-31 |
TN2013000220A1 (en) | 2014-11-10 |
AU2011350396A1 (en) | 2013-07-11 |
US20130273157A1 (en) | 2013-10-17 |
CO6731132A2 (es) | 2013-08-15 |
CL2013001793A1 (es) | 2013-12-06 |
SG10201602311XA (en) | 2016-04-28 |
CA2823166C (fr) | 2019-04-09 |
CN103402500A (zh) | 2013-11-20 |
AR084610A1 (es) | 2013-05-29 |
BR112013014875A2 (pt) | 2016-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34768B1 (fr) | Comprimé orodispersible | |
CA2463134C (fr) | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques | |
EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
EA201071054A1 (ru) | Твердый препарат, растворяющийся во рту | |
TW200624127A (en) | New modified release pellet formulations for proton pump inhibitors | |
PE20130574A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
RU2008130892A (ru) | Твердое лекарственное средство с контролируемым высвобождением | |
JP2008534530A (ja) | 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形 | |
NZ605601A (en) | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof | |
JP2008522989A5 (fr) | ||
JP2015510936A (ja) | 排尿頻度を減少させるための延長放出製剤およびその使用の方法 | |
EP1077687B1 (fr) | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation | |
EA201390979A1 (ru) | Композиции бензимидазолов с модифицированным высвобождением | |
NZ599742A (en) | Improved oral pharmaceutical solid dosage form | |
AR071970A1 (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla | |
US8758818B2 (en) | Oral tablet compositions of dexlansoprazole | |
FR2885526A1 (fr) | Medicament oral a base d'inhibiteur de pompe a protons | |
CA2543497A1 (fr) | Suspensions analgesiques a liberation controlee | |
CA2648538A1 (fr) | Formulation pharmaceutique a liberation rapide orale pour pyridylmethylsulfinyl-benzimidazoles | |
JP2015522658A (ja) | 排尿頻度を減少させるための医薬製剤およびその使用の方法 | |
CA2797809A1 (fr) | Comprime a delitage intestinal | |
RU2012140651A (ru) | Фармацевтический или нутрицевтический состав | |
US11633378B2 (en) | Methods and compositions for delivering mycophenolic acid active agents to non-human mammals | |
MX2015010449A (es) | Composicion farmaceutica multiparticulada que comprende una multitud de dos clases de granulos. | |
JP2017506265A5 (fr) |